Ausbil Investment Management Ltd Invests $127,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Ausbil Investment Management Ltd purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,777 shares of the company’s stock, valued at approximately $127,000.

Several other hedge funds have also bought and sold shares of the business. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares in the last quarter. Stonekeep Investments LLC increased its stake in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares in the last quarter. CWM LLC raised its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Cadent Capital Advisors LLC raised its holdings in Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after buying an additional 1,060 shares during the last quarter. Finally, Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44. Following the sale, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total value of $331,050.00. Following the transaction, the insider now owns 196,941 shares of the company’s stock, valued at approximately $4,346,487.87. The trade was a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,256,067 shares of company stock worth $34,459,485 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 9.9 %

Shares of NYSE:HIMS opened at $37.33 on Friday. The stock has a 50 day moving average of $29.20 and a 200 day moving average of $22.57. The company has a market cap of $8.16 billion, a PE ratio of 84.85 and a beta of 1.31. Hims & Hers Health, Inc. has a 12-month low of $8.51 and a 12-month high of $37.96.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent analyst reports. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.